Browse by subject:
INTRACTABILITY#42 of 56 by βWPaper #47
Pharmacy Benefit Managers
Structural separation legislation. FTC investigation active. Spread pricing ban. Three companies control 80% of the market — they are the buyer, the seller, and the middleman.
WELFARE BETA
candidate beta-W 1.21
source-reported average; admission pending independent channel and denominator review
THEOREM TYPE
Intractability
institutionally reformable
SOURCE STATUS
Summary + deck generated
verified by paper record
OPEN HTML DECK ↗Deck mode is an on-site reading view, not a PowerPoint download.
Theorem status: evidence-traced claim under the cited paper's assumptionsMC interval status: re-estimation required; legacy template bands are withheldWelfare beta is a source-reported candidate average; channel and denominator admission is pendingAnnual industry revenue is the denominator, not profit; both quantities must share the activity boundaryFalsification: show the same game preserving system welfare without changing the payoff structure
1.21
welfare beta
$381B
annual loss ($B/yr)
$315B
annual revenue ($B/yr)
KEY FINDINGS
THE VERTICAL INTEGRATION EXTRACTION FLOOR
Under Spread Extraction (A1), Formulary Distortion (A2), and Regulatory Opacity (A3): Pharmacy Benefit Management intermediation structurally increases drug costs while reducing pharmacy access and medication adherence.
PLAIN ENGLISH
Pharmacy Benefit Managers were designed to negotiate lower drug prices. Instead, they capture the spread between negotiated rebates and pharmacy reimbursement. The rebate is the revenue. The patient pays the list price. The pharmacy absorbs the clawback. The system is an extraction machine disguised as a cost-containment tool.
six-lane CONFLICTORING ADVICE
EVIDENCE & LIMITATIONS
- Theorem status: evidence-traced claim under the cited paper's assumptions
- MC interval status: re-estimation required; legacy template bands are withheld
- Welfare beta is a source-reported candidate average; channel and denominator admission is pending
- Annual industry revenue is the denominator, not profit; both quantities must share the activity boundary
- Falsification: show the same game preserving system welfare without changing the payoff structure
REFERENCES / CITATION STATUS
Reference counts for this manuscript have not been published yet. Treat its citations as unverified until a source list is available.
Loading curated reference section…
EXECUTIVE SUMMARY
The U.S. Pharmacy Benefit Manager (PBM) rebate system—an oligopoly of three vertically integrated intermediaries controlling ~80% of 6.6 billion annual prescriptions—generates $27.6 billion in annual profit for the Big Three PBMs (CVS Caremark, Express Scripts, OptumRx) while imposing welfare costs that dwarf this annual industry revenue. The paper applies the System Asset Pricing Model (SAPM) to
SOURCE QUESTIONS
WHY THIS MATTERS
For the economist
Classified Intractability. The source-reported candidate beta-W of 1.21 is the average system-welfare loss per dollar of industry revenue. Its channel inputs, denominator, and uncertainty packet still require independent admission.
For the regulator
The constraint is institutional, so a well-designed rule can reach a better outcome. Check whether a proven policy model already exists for this domain.
For the executive
This is where a privately efficient decision can degrade the system the business depends on. The governance question is which decision records would make that system cost visible before it is normalized.
For the teacher
An on-site HTML deck and the expanded curriculum cover the argument, the evidence, and the measurement. Use the deck as a self-contained class session, then route deeper through the 45-50h core course or 100+h full curriculum.
For the affected community
In plain terms: who gains from the current arrangement, who pays for it, and what rule change would alter that split. The summary states each without jargon.
RELATED BY WELFARE BETA
Welfare beta is shown on the same scale for each card: annual system-welfare loss divided by annual industry revenue, with both measured on the same domain, same time period, and same activity boundary.
© 2026 Erik Postnieks · Independent Researcher · Salt Lake City